In this interview we talk to Jose Arribas about the challenges facing antiretroviral treatments and the future of long-acting formulations for HIV. What new drugs might we have for this disease in the coming years? Read our interview to find out more.
Browsing: Basic > Drug Development
Take a look at this month’s industry headlines including an FDA approval for Zebraxa, new funding for chikungunya vaccine clinical…
An in vitro study has identified potent antibiotic properties possessed by cannabidiol, discovering activity against Gram-positive bacteria such as Staphylococcus aureus and Streptococcus pneumoniae.
ECCMID 2019 saw the first presentation of the results from ASPECT-NP, a randomized, multi-center Phase III trial evaluating Merck’s ZERBAXA® (ceftolozane–tazobactam) for the treatment of patients with ventilated nosocomial pneumonia. In light of this we spoke to investigators Marin Kollef and Ignacio Martin-Loeches about the rationale behind this trial, its design and the key findings.
Take a look at this month’s industry headlines including US FDA approvals for Mavyret (hepatitis C) and Dengvaxia, a rejection for Contepo and profits for Gilead Sciences.
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Could targeting neighboring bacterial populations help to combat bacterial vaginosis?’, as we ask the authors about the challenges in treating bacterial vaginosis (BV) and the future of this field.
Based on the demonstrated potential of laser-induced vapor nanobubbles to treat bacterial biofilm infections, we provide recommendations for future work in order to further mature this new technology into a promising anti-biofilm approach.
New research has suggested that a combination treatment of gentamicin with azithromycin was almost as effective as the currently used ceftriaxone for treating genital gonorrhea.
Take a look at this month’s industry headlines including news from ViiV Healthcare on long-acting and single dose formulations, sales for Eli Lilly and the possible development of a plague vaccine.
Collaborative research efforts have seen a novel monoclonal antibody, suvratoxumab, complete a Phase II trial targeted towards Staphylococcus aureus. This SAATELLITE study comes as the first clinical trial in the Innovative Medicines Initiative, formed to develop alternative medicines to combat antibiotic resistance.